摘要
Abstract
OBJECTIVE: To observe the clinical efficacy and safety of pitavastatin in the treatment of type 2 diabetes dyslipidoses.METHODS: 80 patients with type 2 diabetes dyslipidoses were randomly divided into control group and treatment group with each group of 40 cases. On the basis of conventional treatment, control group was additional treated with Lovastatin tablets, and treatment group was treated with Pitavastatin tablets for 12 weeks. The changes of blood cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), HbA1c, blood pressure (BP), heart rate(HR), body mass index (BMI), aspartate transaminase (AST), alanine amiotransferase (ALT) and γ-glutamyl transpeptadase (GGT) were observed before and after treatment. RESULTS: The levels of TC, TG, LDL-C were all decreased in two groups after treatment(P＜0.05). The decrease ofTC, TG and LDL-C levels in treatment group was more significant than in control group, there was significant difference(P＜0.05 ). The level of HDL-C in two groups was increased significantly after treatment(P＜ 0.05), especially in treatment group. There was significant difference (P＜0.05). The levels of HbA1c, SBP, HR, BMI, AST and ALT were all decreased in two groups after treatment,but there was no significant difference between 2 groups before and after treatment(P＞0.05). Compared with control group, the level of GGT in treatment group was increased, but there was no significant difference (P＞0.05). CONCLUSION: Pitavastatin can improve types 2 diabetes dyslipidoses, and has little effect on blood glucose, BP, HR, BMI, and enzyme spectrum of liver.关键词
匹伐他汀/糖尿病/脂代谢紊乱分类
医药卫生
